These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 20048722

  • 1. Resistance to novel drug classes.
    Marcelin AG, Ceccherini-Silberstein F, Perno CF, Calvez V.
    Curr Opin HIV AIDS; 2009 Nov; 4(6):531-7. PubMed ID: 20048722
    [Abstract] [Full Text] [Related]

  • 2. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, Perno CF.
    AIDS Rev; 2009 Nov; 11(1):17-29. PubMed ID: 19290031
    [Abstract] [Full Text] [Related]

  • 3. HIV type 1 integrase inhibitors: from basic research to clinical implications.
    Jegede O, Babu J, Di Santo R, McColl DJ, Weber J, Quiñones-Mateu M.
    AIDS Rev; 2008 Nov; 10(3):172-89. PubMed ID: 18820719
    [Abstract] [Full Text] [Related]

  • 4. Novel integrase inhibitors for HIV.
    Prada N, Markowitz M.
    Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
    [Abstract] [Full Text] [Related]

  • 5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K.
    Verh K Acad Geneeskd Belg; 2001 Sep; 63(5):447-73. PubMed ID: 11813503
    [Abstract] [Full Text] [Related]

  • 6. Integrase inhibitors in the treatment of HIV-1 infection.
    Powderly WG.
    J Antimicrob Chemother; 2010 Dec; 65(12):2485-8. PubMed ID: 20852268
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Raltegravir: the first HIV integrase inhibitor.
    Cocohoba J, Dong BJ.
    Clin Ther; 2008 Oct; 30(10):1747-65. PubMed ID: 19014832
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.
    Codoñer FM, Pou C, Thielen A, García F, Delgado R, Dalmau D, Santos JR, Buzón MJ, Martínez-Picado J, Alvarez-Tejado M, Clotet B, Ruiz L, Paredes R.
    Antiviral Res; 2010 Dec; 88(3):281-6. PubMed ID: 20883724
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection.
    Garrido C, Geretti AM, Zahonero N, Booth C, Strang A, Soriano V, De Mendoza C.
    J Antimicrob Chemother; 2010 Feb; 65(2):320-6. PubMed ID: 20007331
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.